Fig 2: Human CAR TCD64t cells are protected from antibody-mediated killing.a, Flow cytometry histograms for anti-CD19 scFv and CD64t expression on human CAR T and CAR TCD64t cells (representative graphs of two independent experiments). b, Flow cytometry histograms for the binding of free IgG1 Fc (anti-TPO IgG1; representative graph of two independent experiments). c, The kinetics of Nalm6 target cell killing by T cells, CAR T cells and CAR TCD64t cells is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). d, The kinetics of Nalm6 target cell killing by CAR TCD64t in the presence and absence of 1 µg ml-1 of anti-CD52 is expressed as hours that it takes for the cell index to drop from 1 to 0.5. Different CAR T cell-to-Nalm6 ratios are shown (mean ± s.d.; three independent replicates per group and timepoint). e,f, Human CAR T and CAR TCD64t cells were challenged in impedance NK cell ADCC (e) and CDC (f) assays with antibodies against HLA (HLA-A2), non-HLA (CD52 and CD3), rhesus blood type antigen D (Rh(D)) and the CAR (anti-CD19 scFv) at 1 µg ml-1 (mean ± s.d.; three independent replicates per group and timepoint).